Science 37® Adds Acclaimed Researcher and Oncologist, Dr. Shaalan Beg to Bolster Therapeutic Depth
Addition of Dr. Beg provides Science 37 with expertise to apply more decentralized clinical trial…
News
Rapid Therapeutic Science Laboratories Announces 1-for-25 Reverse Stock Split
DALLAS, Texas, March 31, 2022 (GLOBE NEWSWIRE) — Rapid Therapeutic Science Laboratories, Inc. (OTC: RTSL)…
Aptose to Present at Canaccord Genuity’s 2022 Horizons in Oncology Virtual Conference
SAN DIEGO and TORONTO, March 31, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or…
Incyclix Bio Announces $30 Million Series B Financing Led by Boxer Capital
Funds to support clinical development of INX-315, the company’s lead Cyclin-Dependent Kinase 2 inhibitor Sid…
Acerus Announces Amendments to Loan Facility
TORONTO, March 31, 2022 (GLOBE NEWSWIRE) — Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP;…
Surface Oncology Achieves $30 Million Milestone with First Patient Dosed in GlaxoSmithKline Phase 1 Study
CAMBRIDGE, Mass., March 31, 2022 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology…
Agile Therapeutics® Announces First Twirla® Commercial Targeting Gen Z
Partners with Award-Winning Director Maya Albanese “Patch and Play” introduces the features of the Twirla…
Abeona Therapeutics Announces Strategy Update and 2021 Financial Results
EB-101 pivotal phase 3 VIITAL™ study in RDEB achieves target enrollment; top-line data expected in…
Auxly Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Outlook for 2022
TORONTO, March 31, 2022 (GLOBE NEWSWIRE) — Auxly Cannabis Group Inc. (TSX ‐ XLY) (OTCQX:…
InflaRx Announces Encouraging Phase III Topline Results from PANAMO Trial of Vilobelimab in Severe COVID-19 Patients
Vilobelimab treatment results in relative reduction in 28-day all-cause mortality of 23.9% compared to placebo…
Windtree Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology…
Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare Fund, an affiliate of CBC Group
CHESTERBROOK, Pa., March 31, 2022 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company…
ObsEva Annual Report 2021
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva,…
BioNTech Announces ADS Repurchase Program
MAINZ, Germany, March 31, 2022 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or the…
XORTX Files IND with US FDA
● Autosomal Dominant Polycystic Kidney Disease – XRx-008 Program IND Filed ● CALGARY, Alberta, March 31,…
Trevena Reports Fourth Quarter and Full Year 2021 Results
— OLINVYK® utilization gaining traction in key target markets Seasoned Biopharma Leader Patricia Drake appointed…
PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2021 Financial Results
Company to host conference call and webcast today, March 31, 2022, at 8:00 AM EDT…
Eloxx Pharmaceuticals Reports Fourth Quarter 2021 Financial and Operating Results and Provides Business Update
Expect topline data from cystic fibrosis (CF) Phase 2 expansion treatment arms evaluating combination with…
Cerevel Therapeutics Announces Upcoming Presentations at AAN 2022
Oral presentation to highlight preclinical data demonstrating robust antiepileptic activity for darigabat in drug-resistant focal…
Autolus Therapeutics Receives EMA Orphan Medical Product Designation for obe-cel for Treatment of Acute Lymphoblastic Leukemia
LONDON, March 31, 2022 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company…